Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020–2022)

Fig. 2

Antimicrobial activity of β-lactamase inhibitor combinations and meropenem against Enterobacterales, CRE, and P. aeruginosa isolated from patients hospitalized with pneumonia in US medical centers (2020–2022). Abbreviations CRE, carbapenem-resistant Enterobacterales; ATM-AVI, aztreonam-avibactam; CAZ-AVI, ceftazidime-avibactam; MEM-VAB, meropenem-vaborbactam; IMI-REL, imipenem-relebactam; TOL-TAZ, ceftolozane-tazobactam. * Inhibited at ≤ 8 mg/L

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us